Biogen Idec (BIIB)

BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (“CNS”). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ), are working within a broader industry shift toward advanced delivery platforms designed to bypass traditional barriers and facilitate rapid, targeted access to the brain. Oncotelic’s approach, which includes a proprietary intranasal nose-to-brain (“N2B”) system that enables rapid therapeutic delivery, reflects a growing recognition that solving CNS delivery, not just drug discovery, may be key to unlocking the next generation of therapies. Oncotelic joins a group of leading biopharma companies focused on cutting-edge therapeutic platforms and large-scale drug development in a range of treatment areas, including Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), CytoDyn Inc. (OTCQB: CYDY) and…

Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself within a growing push to overcome one of modern medicine’s most persistent challenges: delivering therapeutics effectively across the blood-brain barrier. Through its proprietary intranasal nose-to-brain delivery platform, the company is pursuing targeted central nervous system applications spanning Alzheimer’s disease and biodefense, reflecting broader industry recognition that delivery technology may be as critical as drug discovery itself. Oncotelic is part of an innovative therapeutic landscape that includes Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), CytoDyn Inc. (OTCQB: CYDY) and Northwest Biotherapeutics Inc. (OTCQB: NWBO).

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-...

AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain barrier (BBB), a biological defense system that prevents most therapeutics from reaching the central nervous system (CNS). As Alzheimer’s disease cases rise globally and governments intensify focus on biodefense preparedness, the inability to deliver drugs effectively to the brain is emerging as a critical bottleneck in modern medicine. With this in mind, innovative companies, including Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), are working within a broader industry shift toward advanced delivery platforms designed to bypass traditional barriers and facilitate rapid, targeted access to the brain. Oncotelic’s approach, which includes a proprietary intranasal nose-to-brain (N2B) system that enables rapid therapeutic delivery, reflects a growing recognition that solving CNS delivery, not just drug discovery, may be key to unlocking the next generation of therapies. Oncotelic joins a group of leading biopharma companies focused on cutting-edge therapeutic platforms and large-scale drug development in a range of treatment areas, including Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), CytoDyn Inc. (OTCQB: CYDY) and Northwest Biotherapeutics Inc. (OTCQB: NWBO).

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Biogen (NASDAQ:BIIB) reported strong Q1 earnings, beating expectations. However, they cut their FY2026 EPS guidance. Analysts have mixed opinions on buying BIIB stock.

The biotech's growth portfolio continues to add to its overall top line.

Biogen (BIIB) Q1 2026 Earnings Transcript

Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 1.9% year on year to $2.48 billion. Its...

Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before the bell. Here’s what you need to know. Biogen beat analysts’ revenue ex...

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Biogen (BIIB) Q4 2024 Earnings Call Transcript

Biogen (BIIB) Q3 2024 Earnings Transcript

Biogen (BIIB) Q2 2025 Earnings Transcript

Biogen (BIIB) Q3 2025 Earnings Transcript

Check out the companies making headlines yesterday: Cadence Design Systems (NASDAQ:CDNS): Electronic design automation company Cadence Design Systems (NASDAQ...

Biogen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.7%. The stock now trades at $183.50, marking a 25.5% ga...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novav...

What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.6% in the afternoon session after the company received an analyst upgrade from Wells F...

CAMBRIDGE, Mass. and HANGZHOU, China, April 20, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma (“TJ Bio”) today announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio’s exclusive rights to felzartamab in the Greater China Region. With this agreement, Biogen now owns exclusive worldwide rights to felzartamab, which is currently being evaluated in global Phase 3 clinical studies across multiple immune-mediated diseases.

Or is the biotech's best days in the rearview mirror?

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...